NEW YORK (GenomeWeb News) – Biodesix said today that it has expanded a series E offering that raised $8.3 million in December.
The company added $6.1 million in a follow-on sale, bringing total proceeds from the sale of series E preferred shares to $14.4 million.
Existing shareholders of the company provided all funds. The offering will remain open to current shareholders until September of 2014.
Biodesix said that it will use the proceeds to accelerate the sales and marketing of VeriStrat, its serum protein test that helps physicians guide therapy for patients with advanced non-small cell lung cancer.